The risk of developing acquired immunodeficiency syndrome (AIDS) among persons infected by the human immunodeficiency virus (HIV) can be estimated by a variety of immunologic and virologic markers, such as the CD4 + T-lymphocyte count, urinary or serum neopterin, /3 2 -microglobulin, interferon, soluble interleukin-2 recep-tors, presence of HIV p24 antigen, and antibodies to p24 or gpl20 (1) (2) (3) (4) (5) (6) (7) . We have recently shown that the levels of some immunologic markers may significantly predict the risk of developing AIDS as early as 5 years before diagnosis (8) . To assess the absolute risk of the development of AIDS in an HIV-1 seropositive individual, we prospectively evaluated immunologic and virologic markers of AIDS in HIV-positive homosexual men using actuarial methods. As studies of prevalently seropositive subjects are potentially biased because the duration of HIV-infection is unknown (onset bias) (9) , markers were analyzed in relation to the known or estimated time of HIV seroconversion.
MATERIALS AND METHODS

Subjects and study design
Of 131 HIV-1 seropositive homosexual men evaluated approximately annually since 1982 (1), 60 had developed AIDS by the end of 1989. A seroconversion date, defined as the midpoint between the last negative and first positive sample, was available for 47 of the 131 infected men. For the 84 men already infected at the onset of the study, seroconversion dates were estimated using the method of backcalculation to develop regional norms. The average date of seroconversion for men in New York who were seropositive in 1982 was probably June 1980; for those in Washington, DC, it was probably June 1981 (10) . To check the reliability of this approach, the annual and cumulative AIDS incidence rates using these imputed seroconversion dates were examined and found to be very similar to those of subjects in the same cohort with midpoint seroconversion dates (8) .
Laboratory assays
HIV-1 antibodies were determined by a commercial enzyme-linked immunosorbent assay (Electronucleonics Inc., Columbia, MD), and reactive samples were confirmed by Western blot analysis (Biotech Inc., Rockville, MD). The relative proportion of CD4 + T-lymphocytes was measured in lymphocytes that had been frozen and thawed using a fluorescence-activated cell sorter and OKT4 monoclonal antibodies (Ortho Diagnostics Co., Raritan, NJ). Serum neoptenn was retrospectively measured by radioimmunoassay (Neopterin RIAcid, Henning-Berlin, Berlin, Germany), and /3 2 -microglobulin was measured in serum using double-antibody radioimmunoassay (fomicro RIA, Pharmacia, Uppsala, Sweden). Serum interferon was measured in 96-well microtiter plates with the use of human FS-4 fibroblasts; a challenge was performed with the encephalomyocarditis virus, as described elsewhere (11) . A level of >4 international units (IU) was considered positive. HIV-1 p24 antigen was determined with a commercial enzyme-linked immunosorbent assay (Abbott Laboratories, North Chicago, IL). For confirmation of antigen positivity, an HIV-1 p24 neutralization test was performed. Anti-p24 antibodies were also determined using an enzyme-linked immunosorbent assay (Abbott Laboratories). For the determination of anti-p24 antibody titers, an anti-p24 quantitation assay (Abbott Laboratories) was used in accordance with the manufacturer's specifications. Potentially prognostic laboratory markers were measured sequentially at defined time intervals after HIV seroconversion. These intervals were defined in years (±6 months) from the date of seroconversion.
Statistical analysis
The method of Kaplan and Meier (12) was used to estimate AIDS-free survival. For this analysis, the markers were divided into approximate terciles, or analyzed in a dichotomous fashion with the categories absent or present. For comparison of KaplanMeier curves, log-rank statistics were calculated. Cox's proportional hazards model (13) was used to assess the predictive value of the covariates singly and in combination. Generally, the covariates were treated as continuous variables-CD4 + T-lymphocyte proportion, neopterin, /3 2 -microglobulin, and anti-p24 antibodies-or as categorical vari-ables-HIV p24 antigen (absent/present) and interferon (absent/present). Interferon was coded as follows: code 0 (absent), <4 IU; codes 1-5 (present)-code 1, 4 to <8 IU; code 2, 8 to <12 IU; code 3, 12 to <20 IU; code 4, 20 to <50 IU; and code 5, >50 IU. A stepwise procedure was performed to determine the relative importance of the covariates in predicting the progression to AIDS. Since the proportion of CD4 + Tlymphocytes has been well established as a predictive marker of AIDS, all bivariate and multivariate models included this variable.
Comparison and choice of models were based on their 2 log-likelihood estimates. For example, first, all possible univariate models were analyzed; second, all bivariate combinations including the proportion of CD4 + T-lymphocytes at any rate were analyzed; then, third, the best bivariate model according to the 2 log-likelihood estimates was used as the basis for multivariate models with three combinations of markers. More elaborate models were not used, because the full model containing all possible variables did not improve the 2 log-likelihood estimate substantially above the level of three variables. These analyses were performed prospectively to estimate the relative hazard of AIDS following measurements taken at defined time intervals after HIV seroconversion. The time intervals 3 years after seroconversion, 4 years after seroconversion, 5 years after seroconversion, and after the level of CD4 + lymphocytes had dropped below 500/ml were chosen because there were sufficient complete sets of marker measurements for these intervals. Spearman rankorder correlation was used for calculation of correlation coefficients between markers.
RESULTS
AIDS-free survival
Complete sets of marker data were available for 81 of the 131 HIV-seropositive homosexual men; 36 of these 81 men developed AIDS during the observation period. Only data for the 81 subjects with complete sets of marker data were used in the KaplanMeier analysis. As illustrated in KaplanMeier plots (figures 1-6), AIDS-free survival 3 years after HIV seroconversion differed at various levels for immunologic and virologic markers. This was significant for the CD4 + T-lymphocyte proportion, neopterin, /3 2 -microglobulin, interferon, and HIV p24 antigen, but not for anti-p24 antibody (p = 0.06). For example, at 1,525 days (4.18 years), the AIDS-free survival in subjects with a CD4 + T-lymphocyte proportion of <25 percent was zero; it was approximately 60 percent in subjects whose CD4 + Tlymphocyte proportion was between 25 and 35 percent, and 70 percent for those whose CD4 + T-lymphocyte proportion was >35 percent. At this same time interval, 77 percent of the subjects with neopterin levels of <10 nmol/liter were AIDS-free, compared with 56 percent of those with neopterin lev- Time (years after testing) FIGURE 1. Kaplan-Meier plots of the proportion of subjects without AIDS by approximate tercile of the CD4 + T-lymphocyte proportion 3 years after seroconversion. (Key: n, number of HIV-seropositive subjects without AIDS at time 0; vertical tick marks, subjects without AIDS who were censored; the p value for the difference in disease-free survival was derived from the log-rank test). 74 Kramer et al. Time (years after testing) FIGURE 2. Kaplan-Meier plots of the proportion of subjects without AIDS by approximate tercile of serum neopterin 3 years after seroconversion. (Key: n, number of HIV-seropositive subjects without AIDS at time 0; vertical tick marks, subjects without AIDS who were censored; the p value for the difference in disease-free survival was derived from the log-rank test). Time (years after testing) FIGURE 3. Kaplan-Meier plots of the proportion of subjects without AIDS by approximate tercile of &>-microglobulin 3 years after seroconversion. (Key: n, number of HIV-seropositive subjects without AIDS at time 0; vertical tick marks, subjects without AIDS who were censored; the p value for the difference in diseasefree survival was derived from the log-rank test).
els of 10-15 nmol/liter and only 26 percent of those with levels of >15 nmol/liter. With respect to serum interferon, AIDS-free survival was 0 after 2,154 days (5.9 years) when interferon was present, compared with about 53 percent when interferon had been absent. The interval of 3 years after seroconversion was chosen because the marker measurements were most complete at this interval.
Proportional hazards models for AIDS Table 1 shows the results from univariate, bivariate, and multivariate analyses using proportional hazards models to assess the predictive value of the markers singly and in combination. Again, all markers except antip24 antibody proved to be single significant AIDS predictors. Bivariate and multivariate combinations are only displayed for models that include the proportion of CD4 + Tlymphocytes, because the predictive potential of this marker is beyond doubt. As illustrated by the 2 log-likelihood estimates, the model incorporating neopterin, interferon, and the CD4 + T-lymphocyte proportion (2 log-likelihood = -239.65) was the best predictive model, resulting in the following hazard function equation:
where CD4% equals the relative proportion of CD4 + T-lymphocytes. Compared with this model, the full model with all markers included did not add significant information: (difference in 2 log-likelihood: -238.45 + 239.65 = 1.2, p> 0.2).
In addition, we evaluated the prognostic potential of the markers as time-dependent variables. In other words, did the prognostic value of a given marker vary with measurements of this marker at different times in the course of HIV disease? Therefore, we analyzed proportional hazards models for AIDS using as starting points measurements made at different times after HIV seroconversion and after CD4 + T-lymphocyte counts had dropped below 500/ml. Table 2 displays beta coefficients and standard errors for the model incorporating the CD4 + Tlymphocyte proportion, neopterin, and interferon at these various other intervals. One sees that the predictive value of markers can change considerably from one time interval to another. Prognostic models at different times after HIV seroconversion could, therefore, contain different combinations of markers (data not shown).
Prognostic markers for the development of Kaposi's sarcoma
In order to be specific for a given category of AIDS illness, we analyzed prognostic markers in the subgroup of subjects whose only initial manifestation of AIDS was Kaposi's sarcoma as compared with markers in HIV-positive controls who did not develop AIDS during the study period. Since the data were sparse (11 cases), this analysis was performed in a univariate fashion only (table 3) . Despite the small number of subjects, neopterin and /3 2 -microglobulin were both found to be significant predictors of Kaposi's sarcoma (p = 0.0009 and p = 0.044, respectively). Since opportunistic infections were the most frequent initial manifestation of AIDS (43 cases), the predictive markers for this illness category were very similar to those presented above for the entire group of AIDS patients. Table 4 shows the correlations among the six markers from all measurements taken 3 76 Kramer etal. n, number of HIV-seropositive subjects without AIDS at time 0; vertical tick marks, subjects without AIDS who were censored; the p value for the difference in disease-free survival was derived from the log-rank test).
Correlations between markers
years after HIV seroconversion (Spearman rank-order correlation coefficients). In addition to anti-p24 antibody and p24 antigen (r = -0.59, p = 0.0001), ft-microglobulin and neopterin were also very highly correlated (r = 0.74, p = 0.0001).
DISCUSSION
We analyzed the potential of immunologic and virologic markers to predict AIDS in relation to HIV seroconversion, with measurements taken at different time intervals after seroconversion and before the onset of AIDS. When measurements made 3 years after HIV seroconversion were used, various immunologic markers (the proportion of CD4 + T-lymphocytes, neopterin, /3 2 -microglobulin, and interferon) and p24 antigen were significant predictors of AIDS for the next 6 years, that is, up to the ninth year after HIV infection (figures 1-6). A proportional hazards model incorporating neopterin, interferon and the CD4 + Tlymphocyte proportion had the best predictive value for progression of HIV-positive homosexual men to AIDS (table 1) .
It was interesting that the prognostic value of markers could vary considerably during HIV disease (table 2) . A marker may thus be a good predictor shortly after seroconversion but fail to estimate the subsequent risk of AIDS accurately when measured late in the course of HIV infection, or vice versa. Since the variation of estimates may partly be due to the sparse number of subjects, further studies with larger numbers are needed to obtain more precise estimates of the subsequent risk of AIDS for different intervals, and to characterize the exact pattern over time. Nonetheless, our findings clearly indicate that the predictive value of the markers is time-dependent. The following hazard function equation takes this timedependence into account: X(0 = X 0 (0 +... + It should also be noted that longer time since HIV seroconversion was itself predictive of AIDS (data not shown), even in the full model.
We are aware that the date of HIV seroconversion of an HIV-seropositive individual is usually not known in the clinical setting. Therefore, one may conclude that the time-dependence with respect to the predictive value of AIDS progression markers is only of theoretical interest and of no practical importance. However, an approximate seroconversion date can be estimated for many persons with prevalent infections based on the history of specific exposures (e.g., rare anal intercourse, contact with a prostitute, or condom failure) or symptoms compatible with the HIV seroconversion syndrome that may occur in one quarter of all incident HIV infections.
In addition, one must be specific about the AIDS illness category: Markers of im- • AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus. f Note that models were built hierarchically upon the CD4* T-lymphocyte proportion because the predictive value of this marker is well established.
% The regression coefficients refer to the units in parentheses next to the variables. For example, for the univariate model "CD4* T-lymphocytes," the coefficient represents a negative change of 0.0519 related to a unit percentage change in CD4 + T-lymphocytes. For "Interferon (codes 0-5)," the coefficient is related to a change of one code, e.g., from 2 to 3, etc.
§ SE, standard error of the regression coefficient.
mune system stimulation, neopterin and ftmicroglobulin, were significant predictors for Kaposi's sarcoma in our univariate analyses (table 3) . This has already been suggested by a descriptive analysis of our cohort (14) and by another study (15) . However, since the number of subjects was sparse, other markers, such as the CD4 + Tlymphocyte proportion, may also become significant predictors of Kaposi's sarcoma with a larger number of subjects.
The results reported here are in agreement with our earlier findings that significant changes in the CD4 + T-lymphocyte proportion, neopterin, and ft-microglobulin occurred within 1 -2 years after seroconversion in subjects who developed AIDS during the study period (8) . They are also in agreement with our report from early in the HIV epidemic that serum interferon activity predicted AIDS in subjects with hemophilia (16) and with reports from other investigators who found elevated neopterin and /3 2 -microglobulin levels early in HIV infection (17) (18) (19) . Recently, we were able to demonstrate that the risk of AIDS can be predicted with immunologic markers as early as even 1 year after HIV seroconversion (20) , which supports the observation that events occurring soon after or around seroconversion influence the progression to AIDS (21) . Understanding the pathogenesis of immunologically severe HIV seroconversions may provide therapeutic opportunities to reduce the risk of AIDS further.
In our analysis, immunologic markers were superior to HIV p24 antigen in their potential to predict progression to AIDS. Neopterin is a compound of low molecular weight derived from dihydroneopterintriphosphate, an intermediate in the de novo synthesis of tetrahydrobiopterin from guanosine triphosphate. Neopterin was found to be present in high concentrations in supernatants of mixed cultures of mononuclear cells from human peripheral blood and of monocytes and macrophages stimulated by 7-interferon (22) . /3 2 -Microglobulin is a protein of low molecular weight that is present on the surface of all nucleated cells as the constant subunit of class I histocompatibility antigens (23) . Most of the interferon activity that we detected was a-interferon, although complete formal characterization has not been done (7) . Mononuclear cells, including monocytes, natural killer cells, and Blymphocytes, produce a-interferon in response to infections with viruses, other intracellular organisms, and other inducers (24) . Although the specific inducer or indue- The Centers for Disease Control classification system provides a clinical basis for case definition (25) but does not characterize the degree of illness, pathobiology, or prognosis. On the other hand, the "Walter Reed staging classification for HTLV-III/LAV infection" (26) characterizes the progressive nature of the pathobiology and is prognostic. However, the Walter-Reed system requires not only a physical examination and T-cell testing but also delayed hypersensitivity testing with a battery of skin test antigens that must be read by trained personnel 48 hours after application. Our data suggest that a combination of immunologic markers, including the CD4 + T-lymphocyte proportion, neopterin or /3 2 -microglobulin, and serum interferon might provide a convenient alternative method of assessing prognosis in HIV-positive individuals. These serological tests are relatively inexpensive by Western medical standards, with costs in the range of a standard HIV antibody test. Since neopterin and ft-microglobulin are very highly correlated (table 4) , it may be sufficient to determine only one of these two markers.
